TD Asset Management Inc Has $32.55 Million Stock Position in Humana Inc. (NYSE:HUM)

TD Asset Management Inc decreased its stake in shares of Humana Inc. (NYSE:HUM) by 4.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 87,124 shares of the insurance provider’s stock after selling 4,532 shares during the period. TD Asset Management Inc owned 0.07% of Humana worth $32,554,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in HUM. Intech Investment Management LLC boosted its stake in shares of Humana by 46.2% in the 4th quarter. Intech Investment Management LLC now owns 42,287 shares of the insurance provider’s stock valued at $19,359,000 after purchasing an additional 13,356 shares during the last quarter. AdvisorShares Investments LLC bought a new position in shares of Humana in the 4th quarter valued at about $421,000. Sei Investments Co. boosted its stake in shares of Humana by 0.4% in the 1st quarter. Sei Investments Co. now owns 61,897 shares of the insurance provider’s stock valued at $21,462,000 after purchasing an additional 264 shares during the last quarter. Cetera Advisors LLC boosted its stake in shares of Humana by 472.1% in the 1st quarter. Cetera Advisors LLC now owns 10,098 shares of the insurance provider’s stock valued at $3,501,000 after purchasing an additional 8,333 shares during the last quarter. Finally, Cetera Investment Advisers boosted its stake in shares of Humana by 249.0% in the 1st quarter. Cetera Investment Advisers now owns 20,945 shares of the insurance provider’s stock valued at $7,262,000 after purchasing an additional 14,944 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Price Performance

NYSE HUM opened at $357.86 on Friday. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.70. Humana Inc. has a 12-month low of $298.61 and a 12-month high of $530.54. The company has a market capitalization of $43.12 billion, a PE ratio of 22.28, a price-to-earnings-growth ratio of 3.16 and a beta of 0.51. The firm’s 50 day moving average is $367.68 and its 200-day moving average is $347.40.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The company had revenue of $29.54 billion for the quarter, compared to the consensus estimate of $28.52 billion. During the same period last year, the company earned $8.94 earnings per share. The firm’s revenue was up 10.4% compared to the same quarter last year. Equities research analysts anticipate that Humana Inc. will post 16.14 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be issued a $0.885 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.99%. Humana’s dividend payout ratio (DPR) is presently 22.04%.

Analyst Ratings Changes

HUM has been the topic of several recent research reports. TD Cowen raised their target price on shares of Humana from $396.00 to $407.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. JPMorgan Chase & Co. increased their price target on shares of Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a research report on Wednesday, August 21st. Cantor Fitzgerald reiterated a “neutral” rating and issued a $395.00 price target on shares of Humana in a research report on Monday, August 19th. Piper Sandler assumed coverage on shares of Humana in a research report on Wednesday, June 26th. They issued an “overweight” rating and a $392.00 price target on the stock. Finally, Morgan Stanley assumed coverage on shares of Humana in a research report on Monday, June 24th. They issued an “equal weight” rating and a $374.00 price target on the stock. Thirteen analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, Humana currently has an average rating of “Hold” and an average price target of $398.70.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.